Merck and N-Power Medicine Collaborate to Expand Oncology Clinical Trial Access
核心洞察
Merck (搜索) and N-Power Medicine (搜索) are collaborating to broaden oncologist and patient participation in oncology (搜索) clinical research, utilizing N-Power's real-time registry and AI-driven platform.
The collaboration aims to implement multiple trials within the N-Power Medicine (搜索) Network, extending the clinical development model to other oncology (搜索) indications and cancer (搜索) centers.
Walgreens received a $25 million project award to conduct a Phase IV observational study assessing COVID-19 (搜索) vaccine correlates of protection, enhancing public health research.
Merck (搜索), known as MSD outside the United States and Canada, is partnering with N-Power Medicine (搜索) to increase the participation of oncologists and their patients in clinical research. This collaboration leverages N-Power Medicine’s real-time registry and point-of-care platform, which integrates technology, AI, and embedded research staff to streamline clinical research workflows and routine patient care.
Expanding Clinical Trial Access in Oncology
The collaboration aims to implement multiple clinical trials within the N-Power Medicine (搜索) Network. The goal is to broaden this clinical development model to encompass additional oncology (搜索) indications and a wider network of cancer (搜索) centers as the N-Power Medicine Network expands. This initiative addresses a critical need to improve access to clinical trials for a larger and more diverse patient population.
N-Power Medicine's Innovative Platform
N-Power Medicine (搜索)’s platform is designed to provide an integrated and efficient workflow for clinical research and patient care. By combining technology, AI, and on-site research staff, the platform aims to reduce the barriers that often prevent oncologists and patients from participating in clinical trials. This approach has the potential to accelerate the development of new cancer (搜索) therapies and improve patient outcomes.
Walgreens to Conduct Phase IV COVID-19 Vaccine Study
Walgreens has been awarded a project valued at up to $25 million through the Rapid Response Partnership Vehicle (RRPV) to conduct a Phase IV observational clinical study. The study will focus on assessing correlates of protection—responses to a vaccine that predict how well a vaccinated person will be protected from future infections—using COVID-19 (搜索) vaccine data. The RRPV is funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services. This partnership highlights a shared commitment to advancing public health through innovative research and leveraging Walgreens’ extensive network of community pharmacies to enhance access and representation in clinical trials.
Oracle Enhances AI Capabilities for Safety Case Management
Oracle (搜索) has announced new capabilities in its AI-supported Oracle Argus and Safety One Intake solutions. These enhancements are designed to help life science organizations meet evolving regulatory requirements and manage the increasing volume of adverse event case workloads. New features for Argus include smart duplicate search and enhanced end-of-study unblinding. Safety One Intake now offers automated email intake and CRO support. These updates aim to increase productivity, improve data privacy, and enhance reporting.